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Immune modulation of the tumor microenvironment has been reported to partici-
pate in the therapeutic efficacy of many chemotherapeutic agents. Recently, we
reported that liposomal encapsulation of oxaliplatin (l-OHP) within PEGylated lipo-
somes conferred a superior antitumor efficacy to free l-OHP in murine colorectal
carcinoma-bearing mice through permitting preferential accumulation of the
encapsulated drug within tumor tissue. However, the contribution of the immune-
modulatory properties of liposomal l-OHP and/or free l-OHP to the overall antitu-
mor efficacy was not elucidated. In the present study, therefore, we investigated
the effect of liposomal encapsulation of l-OHP within PEGylated liposomes on the
antitumor immunity in both immunocompetent and immunodeficient mice. Liposo-
mal l-OHP significantly suppressed the growth of tumors implanted in immuno-
competent mice, but not in immunodeficient mice. In immunocompetent mice,
liposomal l-OHP increased the tumor MHC-1 level and preserved antitumor immu-
nity through decreasing the number of immune suppressor cells, including regula-
tory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages,
which collectively suppress CD8+ T cell-mediated tumor cells killing. In contrast,
free l-OHP ruined antitumor immunity. These results suggest that the antitumor
efficacy of liposomal l-OHP is attributed, on the one hand, to its immunomodula-
tory effect on tumor immune microenvironment that is superior to that of free
l-OHP, and on the other hand, to its direct cytotoxic effect on tumor cells.
O xaliplatin (l-OHP) is a third-generation platinum agentthat exhibits distinct pharmacological properties com-
pared with earlier-generation agents such as cisplatin and car-
boplatin.(1) Clinically, l-OHP is frequently used as a first-line
antitumor agent for the treatment of advanced colorectal can-
cer in conjunction with other agents. The cytotoxic effect of l-
OHP is exerted through the formation of platinum-DNA
adducts. The intrastrand cross-links formed by l-OHP inhibit
the replication and transcription of DNA, which has a direct
cytotoxic effect against tumor cells.(2) However, its clinical
efficacy is limited, at least in part, by its dose-limiting side
effects, including neurotoxicity.(3) In addition, l-OHP alone has
shown limited antitumor efficacy in vivo because of low distri-
bution in tumor tissues.(4) Accordingly, overcoming these limi-
tations requires the use of a nanocarrier system to ensure the
selective and/or adequate delivery of l-OHP to tumor tissue.
Liposomes, a bilayer liquid-filled vesicle made from phos-
pholipids, have been reported to improve the pharmacokinetics
and tumor accumulation of encapsulated drugs. Although con-
ventional liposomes are rapidly taken up by cells of the
mononuclear phagocyte system (MPS), surface modification
with polyethylene glycol (PEGylation) has been proven to pre-
vent recognition by the cells of the MPS, and consequently
prolongs the circulating time of liposomes.(5) Such long circu-
lation characteristics confer passive tumor-targeting to PEGy-
lated liposomes through the so-called enhanced permeability
and retention (EPR) effect.(6)
In an earlier study, we reported that encapsulation of l-OHP
within PEGylated liposomes permitted the preferential accu-
mulation of l-OHP within the tumor tissue through the EPR
effect, resulting in antitumor effects that were greater than
those of free l-OHP in murine colorectal carcinoma-bearing
mice.(7–9) Similarly, Yang et al.(10) also report that intravenous
injection of neutral PEGylated liposome encapsulating l-OHP
induced a significant apoptotic response against a human col-
orectal carcinoma xenograft model. These reports suggest that
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the selective delivery of l-OHP by encapsulation into PEGy-
lated liposome resulted in enhanced antitumor activity.
Many reports have emphasized the contribution of immune
modulation of the tumor microenvironment to the therapeutic
efficacy of many chemotherapeutic agents. Previously, antitu-
mor agents have been considered immunosuppressive and have
been credited with ruining antitumor immunity. However,
recent studies have indicated that some of these antitumor
agents have demonstrated a positive effect on antitumor immu-
nity, and their clinical outcomes partially depend on their
immunomodulation properties.(11) Anthracyclines, particularly
doxorubicin, are known to cause tumor cells to undergo
immunogenic death and to induce tumor-specific immune
responses. In fact, the depletion of CD8+ T cells, which can
kill tumor cells following the recognition of a tumor antigen,
has led to a loss of the antitumor effect of doxorubicin.(12)
This suggests that part of the therapeutic efficacy of doxoru-
bicin depends on CD8+ T cells. In addition, antitumor agents
are known to suppress protumor immunity, which includes reg-
ulatory T cells (Treg),(13) myeloid-derived suppressor cells
(MDSC) (14) and tumor-associated macrophage (TAM).(15)
However, it is unclear whether liposomal antitumor agents
such as l-OHP can modulate antitumor and protumor immu-
nity, which would increase therapeutic efficacy in combination
with its direct tumor-cell killing activity.
In the present study, therefore, we compared the efficacy
and toxicity of free l-OHP and liposomal l-OHP in tumor-bear-
ing immunocompetent mice and in immunodeficient mice. We
here showed that liposomal l-OHP significantly suppressed
protumor immunity and preserved antitumor immunity,
whereas free l-OHP disrupted both forms of immunity. It
appears that the encapsulation of antitumor drugs into lipo-
somes may modulate the immunological effect of these drugs.
Materials and Methods
Materials. Hydrogenated soy phosphatidylcholine (HSPC)
and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-n-(meth-
oxy [polyethylene glycol]-2000) (mPEG2000-DSPE) were gen-
erously donated by NOF (Tokyo, Japan). Cholesterol (Chol)
was purchased from Wako Pure Chemical (Osaka, Japan).
Oxaliplatin (l-OHP) was generously donated by Taiho Pharma-
ceutical (Tokyo, Japan). All lipids were used without further
purification. All other reagents were of analytical grade.
Animals and tumor cells. Male immunocompetent BALB/c
mice (5 weeks old) and male immuno-deficient BALB/c nu/nu
mice (nude mice, 5 weeks old) were purchased from Japan
SLC (Shizuoka, Japan). All animal experiments were evaluated
and approved by the Animal and Ethics Review Committee of
Tokushima University. Colon 26 murine colorectal carcinoma
(C26) was purchased from the Cell Resource Center for
Biomedical Research (Institute of Development, Aging and
Cancer, Tohoku University). The C26 cell line was maintained
in RPMI-1640 medium supplemented with 10% heat-inacti-
vated FBS (Mediatech, VA, USA), 100 units/mL penicillin
and 100 lg/mL streptomycin (MP Biomedicals, CA, USA)
under a humidified atmosphere with 5% CO2/95% air at 37°C.
Preparation of l-OHP-containing PEGylated liposomes. l-OHP-
containing PEGylated liposomes (liposomal l-OHP), composed
of HSPC/Chol/mPEG2000-DSPE (2/1/0.2 molar ratio), were
prepared using a reverse-phase evaporation method that was
described earlier.(7) Unencapsulated l-OHP was removed using
a dialysis cassette (Slide-A-Lyzer, 10000MWCO; Thermo
Fisher Scientific, MA, USA) against 5% dextrose. The
concentration of l-OHP in the liposomes was quantified by an
atomic absorption photometer (Z-5700, Hitachi, Tokyo, Japan)
after destroying the liposomes with 1% Triton-X solution. The
phospholipid concentration of the liposomes was quantified by
phosphorus assay.(16) The mean diameter of the liposomes was
approximately 100 nm, as determined using a NICOMP 380
ZLS (Particle Sizing System, CA, USA).
Treatment of tumor-bearing mice with l-OHP formulations. To
develop tumor-bearing mice, C26 cells (2 9 106 cells) were
inoculated subcutaneously into the left flank of either BALB/c
or BALB/c nude mice. On day 0 when the tumor volume
reached 50–100 mm3, the mice were divided into three groups:
a control group (non-treated), a free l-OHP treatment group
and a liposomal l-OHP treatment group. In the previous study,
we observed that a low dose (4.2 mg/kg) of l-OHP had little
therapeutic effect in a similar experimental animal model.(7)
To obtain the optimal therapeutic and immunomodulatory
effect of l-OHP, in the current study, we selected 8.3 mg/kg of
l-OHP as an experimental dose. On days 0, 7 and 14, free l-
OHP or liposomal l-OHP (8.3 mg l-OHP/kg body) was intra-
venously injected into the mice. Tumor volume was measured
every 3 days using a caliper. The tumor volume was calculated
using the following formula: 0.5 9 (length) 9 (width)2. Body
weight was measured simultaneously and was taken as a
parameter of systemic toxicity.
Treatment of tumor cells with l-OHP formulations
in vitro. C26 cells (105 cells) were seeded onto 12-well plates
24 h prior to drug exposure. The culture medium was replaced
with fresh medium containing free l-OHP or liposomal l-OHP
(15, 300 lM). After culture for 6, 24 and 48 h, the medium
was removed, and the cells were collected. The cell suspension
was used for flow cytometry to examine the expression levels
of MHC class 1 (MHC-1) molecules. [Correction added on 31
July 2017, after first online publication: The incubation times
in the sentence “After culture for 6, 12 and 48 h, the medium
was removed, and the cells were collected” has been changed
to “6, 24 and 48h”.]
Flow cytometry analysis. Tumor cell suspensions were pre-
pared using a gentleMACS Dissociator (Miltenyi Biotec, Ber-
gisch Gladbach, Germany), according to the manufacturer’s
instructions. Briefly, tumors were dissected, chopped into small
pieces and homogenized in RPMI-1640 medium using the gen-
tleMACS Dissociator. After the addition of a mixture of
enzymes (collagenase type I [Wako Pure Chemical] and Dis-
pase II [Roche Diagnostic, Mannheim, Germany]), the suspen-
sions were incubated for 40 min at 37°C. Next, the
suspensions were homogenized again after the addition of
DNase I (Roche Diagnostic). After digestion, the cells were fil-
tered through a cell strainer (100 lm, Becton Dickinson, NJ,
USA).
Spleen cell suspensions were prepared as described previ-
ously.(17) Briefly, single-cell suspensions were prepared using a
gentleMACS Dissociator. The cells were suspended in PBS
containing 0.5 mM EDTA (EDTA-PBS). Red blood cells in
the suspensions were lysed with ammonium chloride solution
(0.83% NH4Cl) for 3 min. Cells were washed with EDTA-
PBS and filtered with a cell strainer to remove clumps. For
in vitro re-stimulation with an antigen, spleen cells (107 cells)
were cultured in vitro with mitomycin C-inactivated C26 cells
(2 9 105 cells) in a 24-well plate for 24 h. During the last
4 h, brefeldin A (Life Technologies, NY, USA) was added
(5 lg/mL) to the culture.
For extracellular staining, the prepared cells were incubated
with the combinations of antibodies (CD8+ T cell; FITC-
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labeled anti-mouse CD8a, Treg; PE-labeled anti-mouse CD4
and Alexa488-labeled anti-mouse CD25, MDSC; PE-labeled
anti-mouse Ly-6G and FITC-labeled anti-mouse CD11b (eBio-
science, CA, USA), TAM; Alexa488-labeled anti-mouse
CD206 (BioLegend, CA, USA) and PE-labeled anti-F4/80
[GmbH, CA, USA]). To examine the expression level of
MHC-1, cells were stained with mouse anti-mouse MHC-1 (H-
2Dd) antibody (AbD serotec, Oxford, UK) and Alexa647-
labeled anti-mouse IgG (Life Technologies). For intracellular
staining, cells were fixed with 4% paraformaldehyde for
20 min, permeabilized with 0.5% saponin for 20 min, and
stained with FITC-labeled anti-mouse IFN-c (eBioscience).
The cells were analyzed using a flow cytometer, Guava Easy-
Cyte Mini (Millipore, MA, USA) or Gallios (Beckman Coul-
ter, CA, USA). The data were analyzed using WinMDI version
2.9 (The Scripps Research Institute, CA, USA).
Statistics. Data are expressed as the mean  SD. Statistical
analysis was performed using a two-tailed unpaired t-test and
one-way ANOVA followed by the Tukey post hoc test using
GRAPHPAD INSTAT software (GraphPad Software, CA, USA).
The level of significance was set at P < 0.05.
Results
Liposomal l-OHP and free l-OHP had greater therapeutic effect
in C26 tumor-bearing immunocompetent mice than in C26 tumor-
bearing immunodeficient mice. C26 tumor-bearing immuno-
competent BALB/c mice received three intravenous injections
(once a week) of either free l-OHP or liposomal l-OHP. Non-
treated mice served as the control. Free l-OHP modestly
reduced the tumor growth compared with the control
(P < 0.05, Fig. 1a). Compared with free l-OHP, liposomal l-
OHP significantly reduced the tumor growth (P < 0.05). In
addition, the treatment of free l-OHP led to a small amount of
body weight loss and a significant reduction in the number of
splenocytes, whereas that of liposomal l-OHP led to even less
body weight loss (Fig. 1b), and the number of splenocytes
(Fig. 1c) was maintained similar to that of an untreated state.
As shown in Figure 1a, liposomal l-OHP exhibited therapeu-
tic effects that were superior to those of free l-OHP in tumor
bearing-immunocompetent mice, which was consistent with
the results shown in our previous study.(7,8) To investigate the
contribution of the immune system to the increased therapeutic
efficacy, either free l-OHP or liposomal l-OHP was injected
into C26 tumor-bearing immunodeficient BALB/c nude mice
(Fig. 2). Surprisingly, the antitumor effect of both liposomal l-
OHP and free l-OHP was diminished in immunodeficient mice;
free l-OHP exhibited no tumor growth inhibition effect in C26
tumor-bearing BALB/c nude mice, while liposomal l-OHP
exhibited a slight level of inhibition (Fig. 2a). In addition, the
treatment with l-OHP formulations caused a slight level of
weight loss (Fig. 2b). To find further direct evidence indicating
that CD8+ T cells are responsible for the liposomal l-OHP-
mediated antitumor effect, the antitumor effect of liposomal
l-OHP was investigated in CD8+ T cell-depleted immunocom-
petent mice which had been treated with anti-CD8 antibody.
As we expected, the therapeutic effect of liposomal l-OHP was
decreased by depletion of CD8+ T cells (Fig. S1). These
results indicate that host immunity, particularly CD8+ T cells,
contributes to the tumor growth suppression effect of l-OHP
formulations.
Liposomal l-OHP and free l-OHP suppressed protumor host
immunity. We next investigated the impact of l-OHP formula-
tions on immunosuppressive cell components in tumor tissue.
After three sequential intravenous injections with l-OHP for-
mulations into C26-bearing immunocompetent BALB/c mice,
the frequency of Treg, MDSC and TAM in the tumors was
determined through flow cytometry. Liposomal l-OHP signifi-
cantly reduced the frequency of Treg (Fig. 3a), MDSC
(Fig. 3b) and TAM (Fig. 3c). In contrast, free l-OHP signifi-
cantly reduced the frequency of Treg (Fig. 3a) and MDSC
(Fig. 3b), but not that of TAM (Fig. 3c). However, there was
no significant difference in terms of the number of Treg,
MDSC and TAM between the free l-OHP-treated group and
Fig. 1. l-OHP formulations exhibited antitumor effect without sys-
temic toxicity in C26 tumor-bearing immunocompetent BALB/c mice.
C26 cells (2 9 106 cells) were inoculated subcutaneously into BALB/c
mice. On days 0, 7 and 14, C26 tumor-bearing mice received three
intravenous injections of either l-OHP (Free l-OHP) or l-OHP-containing
PEGylated liposome (Lipo l-OHP) at a dose of 8.3 mg l-OHP/kg. Non-
treated mice served as the control. (a) Tumor volume. (b) Body
weight. (c) Number of splenocytes. Each value represents the
mean  SD (n = 5). *P < 0.05.
Fig. 2. l-OHP formulations exhibited no antitumor effect in C26
tumor-bearing immunodeficient BALB/c nude mice. C26 cells (2 9 106
cells) were inoculated subcutaneously into BALB/c nude mice. On days
0, 7 and 14, C26 tumor-bearing mice received three intravenous injec-
tions of either Free l-OHP or Liposomal l-OHP at a dose of 8.3 mg l-
OHP/kg. Non-treated mice served as the control. (a) Tumor volume. (b)
Body weight. Each value represents the mean  SD (n = 5). *P < 0.05.
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the liposomal l-OHP-treated group. These results indicate that
both l-OHP formulations eliminated immunosuppressive cells
in the tumor tissue; it was particularly clear that liposomal
l-OHP had eliminated TAM.
Liposomal l-OHP preserved CD8+ T cell-mediated antitumor
immunity. We further investigated the effect of free l-OHP or
liposomal l-OHP treatment on CD8+ T cell populations in the
spleen and tumor tissues. Compared with non-treated mice, the
mice treated with free l-OHP showed smaller numbers of CD8+
T cells in the spleen (Fig. 4a) and a lower frequency of tumor-
infiltrating CD8+ T cells (Fig. 4b). However, as expected, lipo-
somal l-OHP preserved the number of splenic CD8+ T cells
(Fig. 4a) as well as the frequency of tumor-infiltrating CD8+ T
cells (Fig. 4b). To confirm the presence of activated tumor-spe-
cific CD8+ T cells, the numbers of IFN-c+ T cells in CD8+ T
cell populations were determined following the incubation of
splenocytes with C26 cells. Liposomal l-OHP did not increase,
but did maintain, the number of activated tumor-specific CD8+
T cells, while the number of activated tumor-specific CD8+ T
cells was decreased with free l-OHP (Fig. 4c). These results
indicate that liposomal l-OHP treatment preserved CD8+ T
cell-mediated antitumor immunity against C26 tumors in the
immunocompetent BALB/c mice.
Liposomal l-OHP and free l-OHP increased the MHC-1 level of
tumor cells. Tumor cells can escape immune surveillance
through the downregulation of MHC-1 on their surface, which
causes a reduction in their antigenicity.(18) We investigated the
effect of both free l-OHP and liposomal l-OHP treatment on
the level of MHC-1 in C26 tumor cells in vitro and in vivo.
Short exposure did not change the level of MHC-1 molecules
in vitro (Fig. 5a). With more time, however, free l-OHP
increased the expression of MHC-1 in an exposure-dependent
manner. Liposomal l-OHP also increased the expression level
of MHC-1, but to a smaller extent than that of free l-OHP.
Under in vivo conditions, both l-OHP formulations increased
the expression of MHC-1 to a similar extent (Fig. 5b). These
results indicated that both l-OHP formulations increased the
MHC-1 level in vitro and in vivo, which may correspond to
tumor cell antigenicity.
Discussion
Immune modulation of the tumor microenvironment has been
reported to contribute to the antitumor activity of many anti-
cancer drugs.(11) In the current study, we showed that liposo-
mal l-OHP significantly inhibited C26 tumor growth in
immunocompetent mice (Fig. 1a), which is consistent with our
Fig. 3. l-OHP formulations eliminated immunosuppressive cell com-
ponents from tumors. On days 0, 7 and 14, C26 tumor-bearing
immunocompetent BALB/c mice received three intravenous injections
of either Free l-OHP or Liposomal l-OHP. Non-treated mice served as
the control. On day 21, tumors were collected and tumor tissue sus-
pensions were prepared. Those cells were stained with various anti-
bodies before flow cytometry analysis. Cells were gated on size and
expression of each marker. (a) The frequency of Treg (CD4+ CD25+),
(b) MDSC (CD11b+ Gr-1+) and (c) TAM (F4/80+ CD206+) in tumors. The
percentage of each population was calculated by dividing each cell
population number by the total cell number in tumor tissue. Each
value represents the mean  SD (n = 3). **P < 0.01.
Fig. 4. Liposomal l-OHP CD8+ T cell-mediated antitumor immunity.
On days 0, 7 and 14, C26 tumor-bearing BALB/c mice received three
intravenous injections with either Free l-OHP or Liposomal l-OHP.
Non-treated mice served as the control. On day 21, the tumors and
spleens were collected, and cell suspensions were prepared. The sus-
pensions were stained with anti-CD8 antibody and then analyzed
using flow cytometry. (a) The number of CD8+ T cells in the spleens.
(b) The frequency of CD8+ T cells in tumors. The percentage of CD8 +
T cells was calculated by dividing CD8 + T cell number by total cell
number in tumor tissue. (c) On days 0 and 7, C26-bearing BALB/c mice
received two intravenous injections of either Free l-OHP or Liposomal
l-OHP. Non-treated mice served as the control. On day 10, the spleens
were collected and cell suspensions were prepared. The cells were
pulsed with mitomycin C-treated C26 tumor cells in vitro. IFNc+ CD8+
T cells were analyzed through flow cytometry. Each value represents
the mean  SD (n = 3). *P < 0.05, **P < 0.01.
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previous results.(7,8) However, the therapeutic effect was sub-
stantially diminished in immunodeficient nude mice, which is
suggestive of the contribution of the immune system to the
therapeutic effect that was obtained by liposomal l-OHP. Nude
mice lack a thymus, so they cannot generate mature T lympho-
cytes relating to T cell-dependent antitumor immunity. As
shown in Figure 4c, in the immunocompetent mice, liposomal
l-OHP preserved the C26 tumor-specific activated CD8+ T
cells in tumor tissue, thereby indicating the generation of a
CD8+ T cell-mediated antitumor immune response. To the best
of our knowledge, ours is the first study to suggest that liposo-
mal l-OHP elicits a strong antitumor effect on tumor cells
through not only the direct cytotoxic effect of l-OHP against
tumor cells but modulating the antitumor immunity as well.
Conventional anticancer chemotherapy is generally thought
to reduce tumor progression through direct cytotoxic effects on
tumor cells. We also showed that free l-OHP and liposomal
l-OHP had a direct cytotoxic effect on tumor cells in vitro and
in vivo using immunocompetent mice.(8) Several recent studies
have reported that antitumor activities induced by antitumor
agents such as doxorubicin,(12) cyclophosphamide,(13) borte-
zomib(19) and gemcitabine(20) are severely alleviated under
immunocompromised conditions, indicating that their antitu-
mor effects are partially and/or mainly related to the host anti-
tumor immunity. In the same context, in the current study, free
l-OHP failed to exhibit tumor growth suppression in immunod-
eficient nude mice (Fig. 2a). In addition, in immunocompetent
mice, free l-OHP also tended to ruin protumor immunity invol-
ving regulatory T cells (Treg) and myeloid-derived suppressor
cells (MDSC) (Fig. 3), which combine to suppress CD8+ T
cell-mediated antitumor immune responses. Furthermore,
l-OHP increased the expression of MHC-I on tumor cells
(Fig. 5) and made them sensitive to CD8+ T cells, as with
gemcitabine.(21) Therefore, free l-OHP has the ability to
enhance CD8+ T cell-mediated antitumor immunity. However,
due to the lack of T cells in the immunodeficient nude mice,
l-OHP failed to induce antitumor immunity (Fig. 2a). These
data suggest that free l-OHP also elicits its antitumor effect
through T cell-mediated antitumor immunity along with its
inherent cytotoxicity on tumor cells. Accordingly, the liposo-
mal l-OHP-induced antitumor immune response observed in
the present study was due mainly to the antitumor immune
response induced by l-OHP encapsulated in the PEGylated
liposome, in combination with the direct cytotoxicity effect
against tumor cells.
The tumor growth suppression effect of l-OHP in the current
study was much higher in liposomal l-OHP treatment than in
free l-OHP treatment in immunocompetent mice (Fig. 1a). It is
well known that antitumor agents encapsulated in PEGylated
liposomes passively accumulate in tumor tissue through the
EPR effect.(6) Such preferential tumor accumulation increases
the intratumor concentration of antitumor agents. Therefore,
liposomal antitumor agents are believed to achieve a suppres-
sion of tumor growth that is superior to that of free antitumor
agents.(7,8) In the present study, we demonstrated that liposo-
mal l-OHP significantly reduced protumor immunity (Fig. 3)
and preserved antitumor immunity (Fig. 4), while free l-OHP
reduced not only protumor immunity but also antitumor immu-
nity. Free l-OHP is distributed throughout the body following
intravenous injection and thereby causes not only tumor sup-
pression but also adverse reactions such as sensory neuropathy,
nausea, vomiting, diarrhea and hematologic dyscrasias.(3) Such
non-selective l-OHP distribution consequently appeared to
deplete CD8+ T cells in both tumors (Fig. 4b) and the spleen
(Fig. 4a), and it also depleted total splenocytes (Fig. 1c). Con-
servation of T cells through the liposomalization of l-OHP
might be one of the reasons that liposomal l-OHP exhibited a
tumor growth suppressive effect that was higher than that of
free l-OHP in immunocompetent mice (Fig. 1a).
Liposomalization of l-OHP may have other advantages in
l-OHP-mediated antitumor immunity; an increased reduction
of protumor immune cells which have phagocytic activity and
increase of the MHC-1 level of tumor cells possibly corre-
sponding to tumor cell antigenicity. Nano-sized liposomes are
preferentially taken up by phagocytic cells. Protumor immune
cells such as MDSC(22) and TAM(15) have phagocytic activity,
but CD8+ T cells do not. Liposomal l-OHP might lead to a
remarkable reduction in the numbers of MDSC (Fig. 3b) and
TAM (Fig. 3c) through phagocytosis of the liposomes accumu-
lated in a tumor. Thus, the ratio of CD8+ T cell/MDSC and
CD8+ T cell/TAM becomes higher in liposomal l-OHP-treated
mice than in free l-OHP-treated mice. This might lead to a
Fig. 5. l-OHP formulations increased the MHC-1 level of tumor cells. (a) C26 cells were cultured for 6, 24 and 48 h in the presence of Free l-OHP
or Liposomal l-OHP (15, 300 lM). (b) On days 0 and 7, C26 tumor-bearing BALB/c mice received two intravenous injections of either Free l-OHP
or Liposomal l-OHP. Non-treated mice served as the control. On day 10, tumors were collected. The treated cells in vitro and in vivo were stained
with anti-mouse MHC-1 (H-2Dd) antibody and then analyzed using flow cytometry. Each value represents the mean  SD (n = 3). *P < 0.05. [Cor-
rection added on 31 July 2017, after first online publication: In the figure legend of figure 5, the incubation times in the sentence “C26 cells
were cultured for 6, 12 and 48 h in the presence of Free l-OHP or Liposomal l-OHP (15, 300 lM)” has been changed to “6, 24 and 48h”.]
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preservation of antitumor immunity following liposomal l-OHP
treatment. In our previous study, liposomal l-OHP achieved a
much higher tissue concentration of l-OHP in tumors com-
pared with free l-OHP(7,23) and exposed its payload to the
tumor cells for a longer period of time compared with free l-
OHP due to their sustained release characteristics. Accord-
ingly, the released l-OHP might promote immunogenic death
in tumor cells(24) and could increase the MHC-1 level of tumor
cells, possibly corresponding to tumor cell antigenicity.
Immunotherapy is a new class in cancer therapy that exploits
the innate powers of the immune system to fight cancer. How-
ever, single treatments using immunotherapeutic agents has
had limited efficacy in many cases due to the unfavorable
immune environment in tumors. Recently, immunotherapy has
been combined with both chemotherapy(25,26) and radiother-
apy,(27) with the ever-expanding knowledge of the immune-
modulating ability of these therapies. Hazama et al.(28) investi-
gated the efficacy of peptide cancer vaccine combined with
free l-OHP-based chemotherapy for the treatment of colorectal
cancer in a phase II study. Unfortunately, the efficacy of their
combined therapy was relatively low, suggesting that the
vaccine should be combined with other agents to modulate
antitumor immunity. Instead of free l-OHP, the use of liposo-
mal l-OHP, which can modulate protumor and antitumor
immunities, in combination with peptide vaccine may provide
a much stronger therapeutic effect in the treatment of tumors.
Liposomal l-OHP therapy has shown promise when used in
combination with immunotherapy. The study of such combined
treatment is in progress in our laboratory.
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Fig. S1. Depletion of CD8+ T cells attenuated the antitumor effect of liposomal l-OHP in C26 tumor-bearing immunocompetent BALB/c mice.
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